During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed treatment for a patient with chronic ...

Panelists discuss how challenges in implementing emerging Bruton tyrosine kinase inhibitor (BTKi) regimens for ...

that have achieved promising results in Phase I/II studies when available should modify the paradigm of the treatment of elderly patients with CLL. Here, the authors review background data on ...

and symptoms that indicate a more active disease pattern guide treatment initiation for CLL. The International Workshop on CLL has published guidelines. At least one of the following must be ...

Panelists discuss how the clinical implications of emerging Bruton tyrosine kinase inhibitor (BTKi)trials in mantle cell ...

Data are now accumulating on the feasibility of various treatment options even in unfit patients and there is an increased awareness that the chronological age by itself sometimes does not reflect ...

In conclusion, our study reveals that both the mutational complexity and subclonal diversity influence the evolution of CLL. The prognostic impact was evaluated for time to first treatment (TTFT ...

If your CLL is in the early stages, you may not need treatment right away. If you do, your treatment will depend on your cancer stage, symptoms, total health, and preferences. Treatment options ...

Treatment for CLL continues to change. Doctors are using newer targeted cancer drugs. This means a stem cell transplant is now a less common treatment for CLL. You have a transplant using donor cells ...

During a Case-Based Roundtable® event, Catherine Coombs, MD, discussed the BRUIN trial and recent NCCN updates on chronic ...

Also carving out room in the indication is BeiGene’s Brukinsa ... Breyanzi is the first and only cell immunotherapy to enter the CLL and SLL treatment space, which is dominated by BTK inhibitors ...